Weizmann Science Park, Ness Ziona, Israel, June 04 2008 - Kamada, a bio-pharmaceutical company (www.kamada.com)
engaged in the development, manufacturing and marketing of specialty
life-saving therapeutics, announced today of successful interim results in
a Phase II deposition study with its Aerosolized AAT product delivered by
PARI's optimized eFlow® electronic nebulizer to treat Alpha-1 Deficiency
and other respiratory diseases.
According to David Tsur, CEO Kamada "This significant milestone
demonstrates the high potential of the company's Aerosolized AAT product
currently undergoing advanced clinical trials for several indications.
These interim trial results meet our expectations and support the clinical
plan".
According to Pnina Strauss, Clinical Trials & IP Manager "This
next generation product, Aerosolized AAT, holds numerous advantages over
the currently used AAT for intravenous administration. Among these
advantages are greater patient convenience, reduced treatment costs, larger
treatment population and additional potential indications, all pending successful
completion of the company's clinical development plan".
Kamada's aerosolized AAT drug was designated by both the US-FDA and the
European Agency for the Evaluation of Medicinal Products (EMEA) as an
Orphan Drug for Congenital Emphysema and CF as well as for Bronchiectasis
by the US-FDA. This important attribute will allow the company research
funds benefits, waiver of user fees and free scientific advice by the
regulatory authorities. Furthermore, if Kamada is the first company to
successfully complete clinical trials and receive marketing approval in the
US or the EU, the
company shall gain exclusive marketing rights for the duration of seven
years in the US, and for
10 or 12 years in Europe.
About PARI's eFlow®
eFlow®, an electronic, portable
nebulizer, enables extremely efficient aerosolization of liquid medications
via a vibrating, perforated membrane. Compared to other nebulizer systems,
eFlow® can produce aerosols with a very high density of active drug, a
precisely defined droplet size, and a high proportion of respirable
droplets delivered in the shortest possible amount of time. Combined with
its silent mode of operation, small size (it fits in the palm of your
hand), light weight, and battery use, PARI's eFlow® helps reduce the burden
of taking daily inhaled treatments.
About PARI Pharma
PARI Pharma develops aerosol delivery devices and inhaled therapies. Based
on PARI's 100-year history working with aerosols, PARI Pharma specializes
in treatments for pulmonary and nasal administration optimized to advanced
delivery platforms, such as the eFlow®.
About Kamada
Kamada is a public biopharmaceutical company (TASE: KMDA) developing,
producing and marketing a line of specialty life-saving therapeutics using
its proprietary chromatographic purification technologies. Licensed and
marketed in more than 15 countries, several of these specialty therapeutics
hold registered and pending patents and are currently in advanced clinical
trials.
###
|
